From the Research
Buscopan (hyoscine butylbromide) is generally considered safe for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, as it does not have oxidative properties that would put these patients at risk of hemolytic anemia. The mechanism of action of Buscopan, which involves blocking muscarinic receptors to reduce smooth muscle contractions in the gastrointestinal tract, does not interfere with the pentose phosphate pathway affected in G6PD deficiency 1.
Key Points to Consider
- The standard dosage for adults is typically 10-20 mg taken up to four times daily, with a maximum daily dose of 100 mg.
- Patients should be aware of common side effects including dry mouth, constipation, and blurred vision.
- Those with glaucoma, myasthenia gravis, or urinary retention should use Buscopan with caution.
- A recent real-world study found that many medications previously thought to be risky for G6PD-deficient patients were actually prescribed safely without causing hemolysis, highlighting the need for evidence-based guidelines 2.
- While Buscopan itself is safe for G6PD-deficient patients, it's always advisable to inform healthcare providers about the G6PD status when receiving any medication.
Safety and Efficacy
The safety of Buscopan in G6PD-deficient patients is supported by the lack of evidence suggesting it causes hemolytic anemia in these individuals 1, 2. In fact, a study from 2024 found that many medications, including some that were previously considered risky, can be safely prescribed to G6PD-deficient patients without causing hemolysis 2. This suggests that the risk of hemolytic anemia with Buscopan is low.
Clinical Implications
Given the safety profile of Buscopan in G6PD-deficient patients, it can be used as an effective antispasmodic agent in these individuals, provided that the standard precautions and dosage guidelines are followed. Healthcare providers should still be informed of the patient's G6PD status to ensure comprehensive care.